Pub Date : 2024-02-02DOI: 10.3389/fbiom.2024.1348165
Amberlyn Simmons, Olivia Mihalek, Heather A. Bimonte Nelson, Rachael W. Sirianni, S. Stabenfeldt
Sex as a biological variable has been recognized for decades to be a critical aspect of the drug development process, as differences in drug pharmacology and toxicity in female versus male subjects can drive the success or failure of new therapeutics. These concepts in development of traditional drug systems have only recently begun to be applied for advancing nanomedicine systems that are designed for drug delivery or imaging in the central nervous system (CNS). This review provides a comprehensive overview of the current state of two fields of research - nanomedicine and acute brain injury—centering on sex as a biological variable. We highlight areas of each field that provide foundational understanding of sex as a biological variable in nanomedicine, brain development, immune response, and pathophysiology of traumatic brain injury and stroke. We describe current knowledge on female versus male physiology as well as a growing number of empirical reports that directly address sex as a biological variable in these contexts. In sum, the data make clear two key observations. First, the manner in which sex affects nanomedicine distribution, toxicity, or efficacy is important, complex, and depends on the specific nanoparticle system under considerations; second, although field knowledge is accumulating to enable us to understand sex as a biological variable in the fields of nanomedicine and acute brain injury, there are critical gaps in knowledge that will need to be addressed. We anticipate that understanding sex as a biological variable in the development of nanomedicine systems to treat acute CNS injury will be an important determinant of their success.
{"title":"Acute brain injury and nanomedicine: sex as a biological variable","authors":"Amberlyn Simmons, Olivia Mihalek, Heather A. Bimonte Nelson, Rachael W. Sirianni, S. Stabenfeldt","doi":"10.3389/fbiom.2024.1348165","DOIUrl":"https://doi.org/10.3389/fbiom.2024.1348165","url":null,"abstract":"Sex as a biological variable has been recognized for decades to be a critical aspect of the drug development process, as differences in drug pharmacology and toxicity in female versus male subjects can drive the success or failure of new therapeutics. These concepts in development of traditional drug systems have only recently begun to be applied for advancing nanomedicine systems that are designed for drug delivery or imaging in the central nervous system (CNS). This review provides a comprehensive overview of the current state of two fields of research - nanomedicine and acute brain injury—centering on sex as a biological variable. We highlight areas of each field that provide foundational understanding of sex as a biological variable in nanomedicine, brain development, immune response, and pathophysiology of traumatic brain injury and stroke. We describe current knowledge on female versus male physiology as well as a growing number of empirical reports that directly address sex as a biological variable in these contexts. In sum, the data make clear two key observations. First, the manner in which sex affects nanomedicine distribution, toxicity, or efficacy is important, complex, and depends on the specific nanoparticle system under considerations; second, although field knowledge is accumulating to enable us to understand sex as a biological variable in the fields of nanomedicine and acute brain injury, there are critical gaps in knowledge that will need to be addressed. We anticipate that understanding sex as a biological variable in the development of nanomedicine systems to treat acute CNS injury will be an important determinant of their success.","PeriodicalId":73067,"journal":{"name":"Frontiers in biomaterials science","volume":"36 2","pages":""},"PeriodicalIF":0.0,"publicationDate":"2024-02-02","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"139811327","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2024-02-02DOI: 10.3389/fbiom.2024.1348165
Amberlyn Simmons, Olivia Mihalek, Heather A. Bimonte Nelson, Rachael W. Sirianni, S. Stabenfeldt
Sex as a biological variable has been recognized for decades to be a critical aspect of the drug development process, as differences in drug pharmacology and toxicity in female versus male subjects can drive the success or failure of new therapeutics. These concepts in development of traditional drug systems have only recently begun to be applied for advancing nanomedicine systems that are designed for drug delivery or imaging in the central nervous system (CNS). This review provides a comprehensive overview of the current state of two fields of research - nanomedicine and acute brain injury—centering on sex as a biological variable. We highlight areas of each field that provide foundational understanding of sex as a biological variable in nanomedicine, brain development, immune response, and pathophysiology of traumatic brain injury and stroke. We describe current knowledge on female versus male physiology as well as a growing number of empirical reports that directly address sex as a biological variable in these contexts. In sum, the data make clear two key observations. First, the manner in which sex affects nanomedicine distribution, toxicity, or efficacy is important, complex, and depends on the specific nanoparticle system under considerations; second, although field knowledge is accumulating to enable us to understand sex as a biological variable in the fields of nanomedicine and acute brain injury, there are critical gaps in knowledge that will need to be addressed. We anticipate that understanding sex as a biological variable in the development of nanomedicine systems to treat acute CNS injury will be an important determinant of their success.
{"title":"Acute brain injury and nanomedicine: sex as a biological variable","authors":"Amberlyn Simmons, Olivia Mihalek, Heather A. Bimonte Nelson, Rachael W. Sirianni, S. Stabenfeldt","doi":"10.3389/fbiom.2024.1348165","DOIUrl":"https://doi.org/10.3389/fbiom.2024.1348165","url":null,"abstract":"Sex as a biological variable has been recognized for decades to be a critical aspect of the drug development process, as differences in drug pharmacology and toxicity in female versus male subjects can drive the success or failure of new therapeutics. These concepts in development of traditional drug systems have only recently begun to be applied for advancing nanomedicine systems that are designed for drug delivery or imaging in the central nervous system (CNS). This review provides a comprehensive overview of the current state of two fields of research - nanomedicine and acute brain injury—centering on sex as a biological variable. We highlight areas of each field that provide foundational understanding of sex as a biological variable in nanomedicine, brain development, immune response, and pathophysiology of traumatic brain injury and stroke. We describe current knowledge on female versus male physiology as well as a growing number of empirical reports that directly address sex as a biological variable in these contexts. In sum, the data make clear two key observations. First, the manner in which sex affects nanomedicine distribution, toxicity, or efficacy is important, complex, and depends on the specific nanoparticle system under considerations; second, although field knowledge is accumulating to enable us to understand sex as a biological variable in the fields of nanomedicine and acute brain injury, there are critical gaps in knowledge that will need to be addressed. We anticipate that understanding sex as a biological variable in the development of nanomedicine systems to treat acute CNS injury will be an important determinant of their success.","PeriodicalId":73067,"journal":{"name":"Frontiers in biomaterials science","volume":"1 2","pages":""},"PeriodicalIF":0.0,"publicationDate":"2024-02-02","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"139871090","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2024-01-12DOI: 10.3389/fbiom.2023.1343658
Thanh Huyen Phan, Joanne H. Reed
Nanoparticles hold a great potential for therapeutic targeting due to their ability to improve the stability of encapsulated cargo and promote the transport of cargo across membranes to reach to the target site. Most commercially available nanomedicines are simple synthetic liposomes, however, there are numerous side effects due to their off-target delivery and rapid clearance from the bloodstream. Recently, attention has moved toward extracellular vesicles (EVs)–lipid bilayer enclosed particles released by cells (size ranging from 30 to 10,000 nm in diameter). EVs carry and transport lipids, proteins, and nucleic acids from their parental cells to recipient cells, hence they play a key role in intercellular communication. The ability of EVs to cross biological barriers including the blood brain barrier has generated significant attention to explore them as potential biomarkers and natural drug delivery vehicles for various therapeutics and small molecules. EVs have also been implicated in disease pathogenesis by transmitting pathogenic proteins between cells, making them promising biomarkers for disease diagnosis and monitoring. In this review, we will focus on the potential and challenges of EVs as biomarkers, drug delivery vehicles and next-generation therapeutics. Finally, we will explore misfolded protein disorders, amyloidosis, as a case study for how EVs may contribute to disease pathology and how EVs could be applied in the clinic as diagnostic and prognostic biomarkers of amyloid diseases.
{"title":"Extracellular vesicles as next-generation therapeutics and biomarkers in amyloidosis: a new frontier","authors":"Thanh Huyen Phan, Joanne H. Reed","doi":"10.3389/fbiom.2023.1343658","DOIUrl":"https://doi.org/10.3389/fbiom.2023.1343658","url":null,"abstract":"Nanoparticles hold a great potential for therapeutic targeting due to their ability to improve the stability of encapsulated cargo and promote the transport of cargo across membranes to reach to the target site. Most commercially available nanomedicines are simple synthetic liposomes, however, there are numerous side effects due to their off-target delivery and rapid clearance from the bloodstream. Recently, attention has moved toward extracellular vesicles (EVs)–lipid bilayer enclosed particles released by cells (size ranging from 30 to 10,000 nm in diameter). EVs carry and transport lipids, proteins, and nucleic acids from their parental cells to recipient cells, hence they play a key role in intercellular communication. The ability of EVs to cross biological barriers including the blood brain barrier has generated significant attention to explore them as potential biomarkers and natural drug delivery vehicles for various therapeutics and small molecules. EVs have also been implicated in disease pathogenesis by transmitting pathogenic proteins between cells, making them promising biomarkers for disease diagnosis and monitoring. In this review, we will focus on the potential and challenges of EVs as biomarkers, drug delivery vehicles and next-generation therapeutics. Finally, we will explore misfolded protein disorders, amyloidosis, as a case study for how EVs may contribute to disease pathology and how EVs could be applied in the clinic as diagnostic and prognostic biomarkers of amyloid diseases.","PeriodicalId":73067,"journal":{"name":"Frontiers in biomaterials science","volume":"51 36","pages":""},"PeriodicalIF":0.0,"publicationDate":"2024-01-12","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"139533178","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2024-01-10DOI: 10.3389/fbiom.2023.1336842
Carolina Gomez Casas, Anita Shukla
Modulating the immune system using engineered materials is an emerging strategy to combat bacterial infections. Bacteria adopt immune evasion strategies to ensure their survival, ultimately leading to persistence and recurrence of infections. With a rise in antimicrobial resistance and a decrease in antibiotic efficacy, host-directed therapies using immunomodulatory biomaterials are a promising approach to infection management. Here, we review biomaterials developed to modulate the immune system, with an emphasis on innate immunity. We specifically highlight the recent implementation of functionalized surfaces for immunomodulation, including metal ion releasing coatings, stimuli-responsive polymeric coatings, and interleukin releasing surfaces. We also describe immunomodulatory nanoparticles, including lipid-based nanoparticles, biomimetic nanoparticles, and inorganic nanocarriers. Lastly, we explore immunomodulatory hydrogels used primarily for the treatment of wound infections. These approaches offer new strategies for treating bacterial infections and enhancing existing antimicrobial approaches, all while avoiding complications associated with antimicrobial resistance.
{"title":"Engineering immunomodulatory biomaterials to combat bacterial infections","authors":"Carolina Gomez Casas, Anita Shukla","doi":"10.3389/fbiom.2023.1336842","DOIUrl":"https://doi.org/10.3389/fbiom.2023.1336842","url":null,"abstract":"Modulating the immune system using engineered materials is an emerging strategy to combat bacterial infections. Bacteria adopt immune evasion strategies to ensure their survival, ultimately leading to persistence and recurrence of infections. With a rise in antimicrobial resistance and a decrease in antibiotic efficacy, host-directed therapies using immunomodulatory biomaterials are a promising approach to infection management. Here, we review biomaterials developed to modulate the immune system, with an emphasis on innate immunity. We specifically highlight the recent implementation of functionalized surfaces for immunomodulation, including metal ion releasing coatings, stimuli-responsive polymeric coatings, and interleukin releasing surfaces. We also describe immunomodulatory nanoparticles, including lipid-based nanoparticles, biomimetic nanoparticles, and inorganic nanocarriers. Lastly, we explore immunomodulatory hydrogels used primarily for the treatment of wound infections. These approaches offer new strategies for treating bacterial infections and enhancing existing antimicrobial approaches, all while avoiding complications associated with antimicrobial resistance.","PeriodicalId":73067,"journal":{"name":"Frontiers in biomaterials science","volume":"3 3","pages":""},"PeriodicalIF":0.0,"publicationDate":"2024-01-10","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"139439434","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2023-12-20DOI: 10.3389/fbiom.2023.1272913
Nicholas Cornell, Donald Griffin
Glycosaminoglycans (GAGs) are linear polysaccharides commonly used to impart bioactivity into synthetic hydrogels through their broad electrostatic-based protein-binding capabilities. In vivo, GAGs are immobilized through a single linkage point and function as semi-rigid ligands that are capable of limited conformation to proteins to enable high affinity interactions, concentration gradients, and co-signaling. Most GAG immobilization strategies in biomaterials target modification of the GAG repeat unit and produce multiple linkage points which effectively turns the GAG into a multifunctional crosslinker. In this study, we utilize real-time monitoring of binding kinetics to investigate the effects of GAG immobilization approach on GAG-protein binding. We show that GAGs immobilized through a single linkage point (GAGSingle) possess enhanced protein binding compared with GAGs immobilized at several points (GAG¬Multi¬). This effect is demonstrated for multiple GAG and protein types, indicating a broad applicability and importance to GAG use in biomaterials.
{"title":"Investigating the role between glycosaminoglycan immobilization approach and protein affinity","authors":"Nicholas Cornell, Donald Griffin","doi":"10.3389/fbiom.2023.1272913","DOIUrl":"https://doi.org/10.3389/fbiom.2023.1272913","url":null,"abstract":"Glycosaminoglycans (GAGs) are linear polysaccharides commonly used to impart bioactivity into synthetic hydrogels through their broad electrostatic-based protein-binding capabilities. In vivo, GAGs are immobilized through a single linkage point and function as semi-rigid ligands that are capable of limited conformation to proteins to enable high affinity interactions, concentration gradients, and co-signaling. Most GAG immobilization strategies in biomaterials target modification of the GAG repeat unit and produce multiple linkage points which effectively turns the GAG into a multifunctional crosslinker. In this study, we utilize real-time monitoring of binding kinetics to investigate the effects of GAG immobilization approach on GAG-protein binding. We show that GAGs immobilized through a single linkage point (GAGSingle) possess enhanced protein binding compared with GAGs immobilized at several points (GAG¬Multi¬). This effect is demonstrated for multiple GAG and protein types, indicating a broad applicability and importance to GAG use in biomaterials.","PeriodicalId":73067,"journal":{"name":"Frontiers in biomaterials science","volume":"57 4","pages":""},"PeriodicalIF":0.0,"publicationDate":"2023-12-20","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"138954710","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2023-12-07DOI: 10.3389/fbiom.2023.1305379
Halle Lutz, Ashley C. Brown
Sepsis is a common and life-threatening disorder with an alarmingly high mortality rate. Unfortunately, this rate has not decreased significantly over the last decade and the number of septic cases is increasing each year. Despite sepsis affecting millions of people annually, there is still not an established standard of care. The development of a therapy that targets the thromboinflammation characteristic of sepsis is imperative. Until recently, research has focused on uncovering individual pathways to target. As more of the pathophysiology of sepsis has become understood and more biomarkers uncovered, the interplay between endothelial cells, platelets, and leukocytes has emerged as a critical event. Therefore, a multi-targeted approach is clearly required for designing an effective treatment for sepsis. The versatility of biomaterials offers a promising solution in that they can be designed to target and affect multiple pathways and systems and safely inhibit excessive inflammation while maintaining hemostasis. Already, studies have demonstrated the ability of biomaterials to target different processes and stages in sepsis-induced inflammation and coagulopathy. Moreover, some biomaterials offer inherent anti-inflammatory and hemostatic qualities. This review aims to discuss the most recent advancements in biomaterial development designed to address inflammation, coagulopathy, and thromboinflammation.
{"title":"Biomaterials for treating sepsis-induced thromboinflammation","authors":"Halle Lutz, Ashley C. Brown","doi":"10.3389/fbiom.2023.1305379","DOIUrl":"https://doi.org/10.3389/fbiom.2023.1305379","url":null,"abstract":"Sepsis is a common and life-threatening disorder with an alarmingly high mortality rate. Unfortunately, this rate has not decreased significantly over the last decade and the number of septic cases is increasing each year. Despite sepsis affecting millions of people annually, there is still not an established standard of care. The development of a therapy that targets the thromboinflammation characteristic of sepsis is imperative. Until recently, research has focused on uncovering individual pathways to target. As more of the pathophysiology of sepsis has become understood and more biomarkers uncovered, the interplay between endothelial cells, platelets, and leukocytes has emerged as a critical event. Therefore, a multi-targeted approach is clearly required for designing an effective treatment for sepsis. The versatility of biomaterials offers a promising solution in that they can be designed to target and affect multiple pathways and systems and safely inhibit excessive inflammation while maintaining hemostasis. Already, studies have demonstrated the ability of biomaterials to target different processes and stages in sepsis-induced inflammation and coagulopathy. Moreover, some biomaterials offer inherent anti-inflammatory and hemostatic qualities. This review aims to discuss the most recent advancements in biomaterial development designed to address inflammation, coagulopathy, and thromboinflammation.","PeriodicalId":73067,"journal":{"name":"Frontiers in biomaterials science","volume":"55 2","pages":""},"PeriodicalIF":0.0,"publicationDate":"2023-12-07","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"138593203","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2023-11-24DOI: 10.3389/fbiom.2023.1285386
M. B. Monroe, David Fikhman
The overuse of antibiotics to treat bacterial infections along with bacteria’s propensity to form biofilm communities has resulted in an alarming rise in drug-resistant microbes. Current approaches to infection surveillance and biofilm clearance in wounds are severely limited, requiring new biomaterials-based strategies to address this problem. To that end, a range of antimicrobial smart materials have been developed that change their properties in response to bacteria-induced external stimuli, providing tools with an additional level of complexity for defending against microbes. Researchers have tried to tackle this issue using materials that respond to the unique pH, temperature, and enzymatic changes that are induced by bacteria in wounds. These environmental responses are coupled with mechanisms to kill surrounding bacteria and/or to signal infection. For example, bacteria-responsive biomaterial solubilization (transition from non-solubilized solid material to solubilized liquid solution), swelling (volumetric increase due to absorption of surrounding media), de-swelling, degradation, or shape change can be coupled with drug release and/or activation or biofilm disruption, inhibition, or destruction. These materials provide a foundation for future work and improvements related to enhanced infection surveillance, increased specificity of infection response, and effective clearance of biofilms from wound surfaces.
{"title":"Mini-review antimicrobial smart materials: the future’s defense against wound infections","authors":"M. B. Monroe, David Fikhman","doi":"10.3389/fbiom.2023.1285386","DOIUrl":"https://doi.org/10.3389/fbiom.2023.1285386","url":null,"abstract":"The overuse of antibiotics to treat bacterial infections along with bacteria’s propensity to form biofilm communities has resulted in an alarming rise in drug-resistant microbes. Current approaches to infection surveillance and biofilm clearance in wounds are severely limited, requiring new biomaterials-based strategies to address this problem. To that end, a range of antimicrobial smart materials have been developed that change their properties in response to bacteria-induced external stimuli, providing tools with an additional level of complexity for defending against microbes. Researchers have tried to tackle this issue using materials that respond to the unique pH, temperature, and enzymatic changes that are induced by bacteria in wounds. These environmental responses are coupled with mechanisms to kill surrounding bacteria and/or to signal infection. For example, bacteria-responsive biomaterial solubilization (transition from non-solubilized solid material to solubilized liquid solution), swelling (volumetric increase due to absorption of surrounding media), de-swelling, degradation, or shape change can be coupled with drug release and/or activation or biofilm disruption, inhibition, or destruction. These materials provide a foundation for future work and improvements related to enhanced infection surveillance, increased specificity of infection response, and effective clearance of biofilms from wound surfaces.","PeriodicalId":73067,"journal":{"name":"Frontiers in biomaterials science","volume":"30 1","pages":""},"PeriodicalIF":0.0,"publicationDate":"2023-11-24","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"139241775","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2023-11-16DOI: 10.3389/fbiom.2023.1279358
Maneesha Sahni, Emily S. Day
Endometriosis is an incurable gynecologic disease characterized by endometrial-like tissue growth outside of the uterine cavity. It affects approximately 10% of reproductive age women, who endure pelvic pain during periods and/or sexual intercourse and who suffer from reduced fertility and diminished quality of life due to the side effects of current treatments. To improve the management and prognosis of endometriosis patients, researchers have recently begun to develop nanoparticle-based diagnostics and treatments that are more effective and less invasive than existing approaches. This review discusses the current state of the field and highlights considerations for the continued development of nanotechnologies for the diagnosis and treatment of endometriosis.
{"title":"Nanotechnologies for the detection and treatment of endometriosis","authors":"Maneesha Sahni, Emily S. Day","doi":"10.3389/fbiom.2023.1279358","DOIUrl":"https://doi.org/10.3389/fbiom.2023.1279358","url":null,"abstract":"Endometriosis is an incurable gynecologic disease characterized by endometrial-like tissue growth outside of the uterine cavity. It affects approximately 10% of reproductive age women, who endure pelvic pain during periods and/or sexual intercourse and who suffer from reduced fertility and diminished quality of life due to the side effects of current treatments. To improve the management and prognosis of endometriosis patients, researchers have recently begun to develop nanoparticle-based diagnostics and treatments that are more effective and less invasive than existing approaches. This review discusses the current state of the field and highlights considerations for the continued development of nanotechnologies for the diagnosis and treatment of endometriosis.","PeriodicalId":73067,"journal":{"name":"Frontiers in biomaterials science","volume":"11 2","pages":""},"PeriodicalIF":0.0,"publicationDate":"2023-11-16","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"139267410","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2023-11-13DOI: 10.3389/fbiom.2023.1298894
María del Mar Sánchez-Martín, Esther Giraldo, Fernando Gisbert Roca, Ana Alastrue-Agudo, Cristina Martínez-Ramos, Manuel Monleón Pradas, Victoria Moreno-Manzano
Effective spinal cord injury (SCI) treatment remains a significant challenge, given the complex nature of the primary injury and associated devastating loss of neural activity. Neural progenitor cell (NPC)-based therapy has emerged as a potent strategy for the treatment of SCI. However, the invasive nature of direct cell transplantation and the need to enhance graft integration into host tissue remain critical issues. We implemented an improved combinatorial approach to SCI treatment by functionalizing electrospun poly-lactic acid (PLA) membranes that support the sustained delivery of curcumin (PLA-curcumin) and act as a carrier for NPC for local transplantation. In vitro experiments demonstrate that curcumin prevents harmful oxidative and inflammatory stress by preventing death and inhibiting NF-κB activation (mimicked by treatment with hydrogen peroxide or lipopolysaccharide acid). Curcumin also enhances neurite-like outgrowth in NPC and cortical neurons in culture, which may enhance neural connectivity. In vivo transplantation of NPC on a PLA-curcumin electrospun membrane enables cell migration, reduces injured area size, and increases neuronal fiber preservation to induce a slowing of acute neural damage.
{"title":"Acute transplantation of NPC on electrospun poly-lactic acid membranes containing curcumin into the injured spinal cord reduces neuronal degeneration","authors":"María del Mar Sánchez-Martín, Esther Giraldo, Fernando Gisbert Roca, Ana Alastrue-Agudo, Cristina Martínez-Ramos, Manuel Monleón Pradas, Victoria Moreno-Manzano","doi":"10.3389/fbiom.2023.1298894","DOIUrl":"https://doi.org/10.3389/fbiom.2023.1298894","url":null,"abstract":"Effective spinal cord injury (SCI) treatment remains a significant challenge, given the complex nature of the primary injury and associated devastating loss of neural activity. Neural progenitor cell (NPC)-based therapy has emerged as a potent strategy for the treatment of SCI. However, the invasive nature of direct cell transplantation and the need to enhance graft integration into host tissue remain critical issues. We implemented an improved combinatorial approach to SCI treatment by functionalizing electrospun poly-lactic acid (PLA) membranes that support the sustained delivery of curcumin (PLA-curcumin) and act as a carrier for NPC for local transplantation. In vitro experiments demonstrate that curcumin prevents harmful oxidative and inflammatory stress by preventing death and inhibiting NF-κB activation (mimicked by treatment with hydrogen peroxide or lipopolysaccharide acid). Curcumin also enhances neurite-like outgrowth in NPC and cortical neurons in culture, which may enhance neural connectivity. In vivo transplantation of NPC on a PLA-curcumin electrospun membrane enables cell migration, reduces injured area size, and increases neuronal fiber preservation to induce a slowing of acute neural damage.","PeriodicalId":73067,"journal":{"name":"Frontiers in biomaterials science","volume":"35 16","pages":"0"},"PeriodicalIF":0.0,"publicationDate":"2023-11-13","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"136282109","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2023-11-10DOI: 10.3389/fbiom.2023.1260402
Paulina Wiśniewska, Mohammad Reza Saeb, Sidi A. Bencherif
Biomaterials undergo a transformative journey, from their origin as renewable resources to the manufacturing plants where they are processed and stored, until they fulfill their intended therapeutic or diagnostic purposes and become medical waste. However, during this life cycle, biomaterials can be susceptible to contamination and subsequent degradation through various mechanisms such as hydro-mechanical, thermal, or biochemical processes in water, soil, or air. These factors raise significant concerns regarding biological safety. Additional complexities arise from the potential amalgamation of biomaterials with other materials, either of the same kind or different types. Use of biomaterials influences their porosity, surface chemistry, and structural strength, and these factors affect biomaterials’ reusability. Given the multitude of materials, processing parameters, sustainability requirements, and the limitation of natural resources, the recycling of biomaterials becomes necessary. Unfortunately, this topic has received limited attention thus far. In this context, this perspective provides a brief overview, analysis, and classification of reports on biomaterials recycling, aiming to initiate a discussion on this frequently overlooked subject. We highlight the challenges related to energy consumption and environmental pollution. However, the lack of established protocols and reporting on biomaterials recycling prevents a comprehensive understanding of these challenges and potential solutions. Nevertheless, addressing these issues can lead to more efficient resource use and reduced environmental impact in the field of biomaterials.
{"title":"Biomaterials recycling: a promising pathway to sustainability","authors":"Paulina Wiśniewska, Mohammad Reza Saeb, Sidi A. Bencherif","doi":"10.3389/fbiom.2023.1260402","DOIUrl":"https://doi.org/10.3389/fbiom.2023.1260402","url":null,"abstract":"Biomaterials undergo a transformative journey, from their origin as renewable resources to the manufacturing plants where they are processed and stored, until they fulfill their intended therapeutic or diagnostic purposes and become medical waste. However, during this life cycle, biomaterials can be susceptible to contamination and subsequent degradation through various mechanisms such as hydro-mechanical, thermal, or biochemical processes in water, soil, or air. These factors raise significant concerns regarding biological safety. Additional complexities arise from the potential amalgamation of biomaterials with other materials, either of the same kind or different types. Use of biomaterials influences their porosity, surface chemistry, and structural strength, and these factors affect biomaterials’ reusability. Given the multitude of materials, processing parameters, sustainability requirements, and the limitation of natural resources, the recycling of biomaterials becomes necessary. Unfortunately, this topic has received limited attention thus far. In this context, this perspective provides a brief overview, analysis, and classification of reports on biomaterials recycling, aiming to initiate a discussion on this frequently overlooked subject. We highlight the challenges related to energy consumption and environmental pollution. However, the lack of established protocols and reporting on biomaterials recycling prevents a comprehensive understanding of these challenges and potential solutions. Nevertheless, addressing these issues can lead to more efficient resource use and reduced environmental impact in the field of biomaterials.","PeriodicalId":73067,"journal":{"name":"Frontiers in biomaterials science","volume":" 8","pages":"0"},"PeriodicalIF":0.0,"publicationDate":"2023-11-10","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"135191277","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
京公网安备 11010802042870号
京ICP备2023020795号-1
扫码关注我们
求助内容：
应助结果提醒方式：